Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The National Comprehensive Cancer Network (NCCN) has published its first-ever clinical guidelines for Pediatric Bone Sarcoma, with a focus on Ewing sarcoma — the second most common primary bone tumor in children and adolescents. The guidelines give care teams a clear roadmap for diagnosis, treatment, and supportive care. Early-stage survival sits at 81%, but drops sharply to 41% once the disease spreads.
The National Comprehensive Cancer Network (NCCN) has published a major milestone in pediatric oncology: the first-ever NCCN Clinical Practice Guidelines for Pediatric Bone Sarcoma. The guidelines focus on Ewing sarcoma and other undifferentiated round cell sarcomas — a rare but serious cancer that most commonly strikes teenagers between the ages of 15 and 19. Symptoms like persistent pain or swelling in the limbs or pelvis can easily be mistaken for typical teen bone issues, making early X-ray evaluation a critical first step.
The guidelines are designed to give clinicians, nurses, pharmacists, and families a clear, evidence-based roadmap — reducing the risk of both over- and under-treatment. Experts on the panel emphasized that teens face unique challenges during intensive cancer treatment, including disruptions to their developing sense of independence, making a coordinated, knowledgeable care team essential.
By the Numbers:
Why it matters: Pediatric cancers differ meaningfully from adult cancers in biology, treatment, and psychosocial impact. These guidelines fill a long-standing gap, giving care teams worldwide a standardized, freely accessible framework to optimize outcomes for one of the most vulnerable patient populations.
